Last week, WarRoom’s Natalie Winters uncovered millions of dollars in funding, awarded primarily to the Department of Veteran’s Affairs and DoD, to massively ramp up COVID testing and implement other COVID-19 related measures.
This was just a few days after the NIH appointed Dr. Jeanne Marrazzo, a pro-lockdown and mandatory vaccine advocate, as the replacement for Dr. Fauci.
Thegatewaypundit.com reports: To further the suggestion that another lockdown scare is in the forecast, on Tuesday, the US Department of Health and Human Services announced funding of $1.4 billion to “support the development of a new generation of tools and technologies to protect against COVID-19 for years to come” according to a press release.
“Project NextGen is a key part of the Biden-Harris Administration’s commitment to keeping people safe from COVID-19 variants,” said HHS Secretary Xavier Becerra. “These awards are a catalyst for the program – kickstarting efforts to more quickly develop vaccines and continue to ensure availability of effective treatments.”
Project NextGen, a $5 billion initiative led by ASPR’s Biomedical Advanced Research and Development Authority (BARDA) in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), coordinates across the federal government and the private sector to advance innovative vaccines and therapeutics into clinical trials, regulatory review, and potential commercial availability for the American people. The project builds on a better understanding of COVID-19 – with HHS developing, using, and constantly re-evaluating the strengths and weaknesses of current vaccines and therapeutics for over three years.
Recipients of the awards include:
- $1 billion to four BARDA Clinical Trial partners to support vaccine Phase IIb clinical trial studies: ICON Government and Public Health Solutions, Inc of Hinckley, Ohio; Pharm-Olam, LLC, of Houston, Texas; Technical Resources Intl (TRI), Inc, of Bethesda, Maryland; and Rho Federal Systems, Inc., Durham, North Carolina.
- $326 million to Regeneron to support the development of a next-generation monoclonal antibody for COVID-19 prevention.
- $100 million to Global Health Investment Corp. (GHIC), the non-profit organization managing the BARDA Ventures investment portfolio to expand investments in new technologies that will accelerate responses in the future.
- $10 million to Johnson & Johnson Innovation (JLABS) for a competition through Blue Knight, a BARDA-JLABS partnership.
The press release claims that their partnership with Regeneron will help develop a “novel monoclonal antibody that will protect people who do not respond to or cannot take existing vaccines,” despite their attempts to limit the distribution in Florida in 2021.
On Friday, Joe Biden announced that he plans to request more funding from Congress to develop a new COVID vaccine “that works.”
“I signed off this morning on a proposal we have to present to the Congress a request for additional funding for a new vaccine that is necessary, that works,” Biden told the reporters while vacationing in Lake Tahoe.
Biden warned that everyone will get it despite their previous vaccination status.
“It will likely be recommended that everybody get it no matter whether they’ve gotten it before or not,” he added.
Watch:
NEW – Biden Says New COVID Shots 'That Work' May Be on the Way for All Americans
— Chief Nerd (@TheChiefNerd) August 26, 2023
"I signed off this morning on a proposal we have to present to the Congress – a request for additional funding for new vaccine that is necessary that works...Tentatively it is recommended, it would… pic.twitter.com/uYBdOQOK4o
(Article by Sean Adl-Tabatabai republished from ThePeoplesVoice.tv)
